Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis
Chan B, Stanley G, Kortright K, Vill A, Modak M, Ott I, Sun Y, Würstle S, Grun C, Kazmierczak B, Rajagopalan G, Harris Z, Britto C, Stewart J, Talwalkar J, Appell C, Chaudary N, Jagpal S, Jain R, Kanu A, Quon B, Reynolds J, Teneback C, Mai Q, Shabanova V, Turner P, Koff J. Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. Nature Medicine 2025, 31: 1494-1501. PMID: 40301561, PMCID: PMC12092284, DOI: 10.1038/s41591-025-03678-8.Peer-Reviewed Original ResearchConceptsPhage therapyCystic fibrosisEvidence of trade-offsTreated with phagesEvolutionary trade-offClinical impact of antimicrobial resistanceMultidrug-resistant Pseudomonas aeruginosaBacterial virulenceAntimicrobial resistance crisisLytic virusesDecrease antibiotic resistanceSputum microbiomePhageBacteriophage therapyImpact of antimicrobial resistanceAntibiotic resistanceResistance crisisStandard antibioticsAntimicrobial resistanceSputum densityMultidrug resistancePulmonary infectionCompassionate basisClinical courseMedian age
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply